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Abstract
The heterocyclic carboxyborane amines were found to be potent cytotoxic agents in the murine L1210
lymphoid leukemia and human HeLa suspended carcinoma cells. These agents were observed to inhibit
HeLa DNA topoisomerase II activity--- 200 tM and L1210 topoisomerase II activity _> 100 tM. These
agents did not cause DNA protein linked breaks themselves, but upon incubation for 14-24 hr did
enhance the ability of VP-16 to cause cleavable complexes. The heterocyclic amineboranes inhibited
DNA synthesis and caused DNA strand scission. They were additive with VP-16 in affording these
results as well as inhibiting colony growth of L1210 cells after co-incubation for hr. The agents
inhibited in vitro PKC phosphorylation of both L1210 lymphoid leukemia and human topoisomerase II
enzyme.
Introduction
Previously, a series of cyano-, carboxy-, carboxymethoxy-, and carbamoylborane adducts of heterocyclic
amines were shown to be potent antineoplastic agents in the Lewis lung and P388 lymphocytic leukemia
screens at 20 mg/kg/day in mice. Furthermore, they demonstrated significant cytotoxic activity in human
Tmolt3 lymphoblastic leukemia, HeLa-S uterine carcinoma, KB nasopharynx, colorectal
adenocarcinoma SW480, and osteosarcoma and murine L1210 lymphoid leukemia cells [1 ]. A mode of
action study in L1210 cells demonstrated that DNA synthesis and purine syntheses were preferentially
inhibited with significant inhibition at regulatory enzymatic sites such as PRPP-amido transferase, IMP
dehydrogenase, dihydrofolate reductase, nucleoside kinases which resulted in a reduction of
deoxyribonucleotide pools. Furthermore, LI210 DNA strand scission was evident after 24 hr.
incubation with the agents, but the compounds did not alkylate the bases of DNA, intercalate between
base pairs ofDNA or cause cross linking ofDNA strands ]. Thus, the purpose of the following study
is to characterize the reasons why the drugs cause DNA strand scission.
Methods
Compounds 1-7 were previously synthesized and the chemical and physical characteristics reported [3]
[Table ]. All radioisotopes were purchased from New England Nuclear (Boston, MA) unless otherwise
indicated. Radioactivity was determined in a Fisher Scintiverse scintillation fluid with correction for
quenching. Substrates and cofactors were obtained from Sigma Chemical Co. (St. Louis, MO).
Cytotoxicity
Compounds 1-7 were tested for cytotoxic activity by homogenizing drugs in a mg/ml solution in 0.05%
Tween 80/H_O. These solutions were sterilized by passing them through an acrodisc (0.45 t). The
murine L20 lymphoid leukemia and the human HeLa-S uterine carcinoma cell lines were maintained
culture following standard literature techniques. Geran et al.’s protocol [2] was used to assess the
cytotoxicity of the compounds and standards in each cell line. Values for cytotoxicity were
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expressed as EDso tg/ml, i.e. the concentration of the compound inhibiting 50% of cell growth. EDso
values were determined by the trypan blue exclusion technique. A value of less than 4 tg/ml was
required for growth inhibition activity to be considered significant.
Table 1 Structures ofCompounds
N(H)BHCOOH
1. Piperidine carboxyborane
O N(H)BH2COOH
3. Morpholine carboxyborane
//N(H)BH2COOH
,. 4-Methyl piperidine carboxyborane
H3CNx,NBH2COOH
7. N-Methyl imidazole carboxyborane
HN N(H)BH2COOH
k____/
2. Piperazine carboxyborane
O N(CH3)BH2COOH
\ /
4. 4-Phenyl piperidine carboxyborane
H3C---Nkz’N(H)BH2COOH
\ _/
6. 4-Methyl piperidine carboxyborane
DNA Synthesis
Incorporation of 3H-thymidine into DNA of 106 L1210 or HeLa-S cells was determined, tt The
compounds were tested at 25, 50 and 100 tM for inhibition of DNA synthesis over 60 min [3]. The
assay reaction was stopped with N PCA + 1% Na P~P, collected on GF/A filters and counted. Select
studies were conducted with compound 2 at 100 tM with and without VP-16 at 40 tM in an analogous
manner.
DNA Strand Scission
The effects of compounds 1-7 on DNA strand scission was determined by the methods of Suzuki et
a/.[4], Pera et a/.[5] and Woynarowski et a/.[6]. L1210 lymphoid leukemia or HeLa-S uterine cells were
incubated with 10 tCi thymidine methyl-3H, 84.0 Ci/mmol for 24 hr at 37C. L1210 cells (107) were
harvested and then centrifuged at 600 g X 10 min in PBS. They were later washed and suspended in ml
of PBS. Lysis buffer (0.5 ml; 0.5 M NaOH, 0.02 M EDTA, 0.01% Triton X-100 and 2.5% sucrose) was
layered onto a 5-20% alkaline-sucrose gradient (5 ml; 0.3 M NaOH, 0.7 KCI and 0.01 M EDTA); this
was followed by 0.2 ml of the cell preparation. After the gradient was incubated for 2.5 hr at room
temperature, it was centrifuged at 12,000 rpm at 20C for 60 min (Beckman rotor SW60). Fractions (0.2
ml) were collected from the bottom of the gradient, neutralized with 0.2 ml of 0.3 N HC1, and
radioactivity maesured. Thermal calf thymus DNA denaturation, U.V. absorption from 220 to 340 nm
and DNA viscosity studies were conducted after incubation of compounds 1-7 at 100 tM at 37C for 24
hr.
P4-Phage Knotted DNA
P4-phage knotted DNA was isolated by the method of Liu and Davis [7]. Cultures of C-117 E. coli were
grown overnight in 5 ml modified Luria Broth (1% bactotryptone, 0.5% yeast extract, 1% NaC1, 1.6 mM
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MgC12, 0.5 mM CaC12, and 1% dextrose). After 18 hr, P4 phage 1:4000 stock dilution (4 ml,-lxl0
Ix
pfu/ml) was used to inoculate the 5 ml overnight culture. Phage was allowed to adsorb by sitting at room
temperature for 10 min. Two L of modified Luria Broth was then inoculated with 4 ml phage infected
overnight culture. The 2 L inoculate was incubated at 37C with vigorous aeration for 4 hr and 20 min,
after which 20 ml 0.5 M EGTA (pH 8) was added. After hr of stirring at 37C, chloroform (4 ml) was
added to ensure complete cell lysis. The entire 2 L of inoculated broth was centrifuged, in 40 ml
aliquots, at 10,000 rpm and 4C, for 10 min, to remove cell debris. The final volume of supernatant
collected was measured and sufficient NaC1, PEG-8000, and MgCI2 were added to make a solution of 0.5
M NaC1, 10% PEG-8000, and 80 mM MgCI2. This mixture was allowed to precipitate at 4C overnight.
After 18 hr the precipitate was pelleted by centrifugation at 10,000 rpm for 10 min. Pellets were
combined and resuspended in 15 ml P4 diluent 1% NH4OAc, 80 mM MgCI2, 10 mM Tris-HC1 (pH
7.2)] and repelleted. This process was repeated. Supernatants from the previous procedure were collected
and centrifuged at 25,000 rpm for 4 hr. The resulting pellet, containing phage capsids and phage heads,
was resuspended in 45 ml of P4 diluent and the phage solution was weighed. For every gram of phage
solution, 0.632 g ultra pure CsC1 was added. The CsC1/phage solution was placed in ultracentrifuge
tubes and topped off with mineral oil. The CsCl/phage solution was centrifuged at 24,000 rpm, 4C, for
3 days. Two "milky" colored bands were apparent after 3 days; upper band P4 phage capsids, lower
band P4 heads (containing knotted DNA). The bands were collected via a syringe and were dialyzed
with P4 diluent (2 L) using 18 mm dialysis tubing. P4 heads were extracted with an equal volume of
ultrapure buffered phenol. The aqueous layer was separated and 2 volumes of 99 % ethanol were added
and samples were placed at -20C overnight to precipitate the knotted DNA. The precipitate was pelleted
at 10,000 rpm for 5 min and was resuspended in 10mM Tris (pH 8), lmM EDTA, 0.1 M NaC1.
DNA-Topoisomerase II
L1210 or HeLa-S DNA-topoisomerase II was isolated by the method of Miller, et a/.[8] by pelleting
approximately 108 cells by centrifugation at 2500 rpm for 4 min. This pellet was then washed by
resuspending in sterile PBS (pH 7.4) and pelleting again. Next, the pelleted cells were resuspended in
buffer solution containing 0.25 M sucrose, 20 mM potassium phosphate (pH 7.5), 2 mM MgC12, mM
dithiothreitol (DTT), mM spermidine, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF),
and mM Na2S2Otl], at 4C. Cell membranes were lysed by addition of a volume of Triton X-100,
equivalent to 1/100 of the total cell suspension, in concert with Dounce homogenization. Complete cell
lysis was determined by visualization of a small aliquot of cell homogenate stained with trypan blue
(0.4%). An equal volume of buffer solution containing 1.75 M sucrose was added to cell suspension and
mixed by gently swirling. After mixing the total volume was loaded on a sucrose cushion, 1.4 M
sucrose, 20 mM potassium phosphate (pH 7.5), 5 mM MgC12, mM DTT, 0.1 mM EDTA, 0.1 mM
PMSF, and centrifuged at 18,000 rpm for 45 min, at 4C. The sucrose cushion was removed via vacuum
aspiration and the remaining pellet was resuspended in buffer containing 20 mM potassium phosphate
(pH 7.5), 2 mM MgC12, mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, mM D-mercaptoethanol, 10%
glycerin, and 100 mM NaC1. The suspension was incubated at 4C for 30 min and then was centrifuged
at 2,400 rpm for 5 min. Supernatant was collected and the pellet was resuspended in buffer containing
150 mM NaC1 and incubated again for 30 minutes at 4C, followed by centrifugation. The process was
repeated with buffer containing 400mM NaC1. Fractions containing active enzyme, as determined by the
topoisomerase unknotting assay, were kept and stored, after the addition of glycerin to make a 50% v/v
solution, at -70C. Active fractions were diluted to U/tl (1 U was defined as the amount of enzyme
required to completely unknot 150 ng knottedDNA in hr at 37C) with buffer solution.
DNA Unknotting Assay
The effects of the agents on isolated L1210 or HeLa-S DNA topoisomerase II activity was determined
by the method of Miller et a/.[8]. The reaction mixture was prepared to contain the following
components at the following concentrations: 0.05 M Tris (pH 7.5), 0.1 M KC1, 0.01 M MgC12, 30 ktg/ml
bovine serum albumin, 0.5 mM EDTA, 1.0 mM DTT, 1.0 mM ATP. A "4 x Reaction Mix" was
prepared, meaning the components were four times as concentrated as the previously described mix. To
prepare samples a premix was made containing 2.5 tl "4 x Reaction Mix" per sample, 0.25 tl knotted
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DNA/sample, and enough autoclaved, distilled water to bring the volume of each sample up to 8.0 tl. To
each sample reaction 1.0 tl sample compound (at desired concentration) and 1.0 tl topoisomerase II (1
U/tl) was added so that the final volume of each sample reaction was 10 tl. The samples were allowed
to incubate at 37C for hr, at which time 2.5 tl/sample of a stop loading buffer [50% w/v sucrose,
0.5% w/v sodium dodecylsulfate (SDS), and 0.25% w/v bromophenyl blue] was added to stop the
reaction. Each sample, along with an enzyme and DNA control sample, was run for 18 hr using a 0.7%
agarose gel, in electrophoresis buffer (pH 8.0) [90 mM Tris, 2 mM EDTA, 90 mM boric acid], on a
Gibco BRL Horizon 11 X 14 electrophoresis apparatus at 23 v. VP-16 (etoposide) was used as an
internal standard for DNA topoisomerase II inhibitors. Photographs of gels were made by illumination of
gels on a UV light table using Polaroid 667 film. Densitometric analysis was performed by using a GS
300 Transmittance Reflectance Scanning Densitometer and the GS 365 Densitometry Program (version
2) for personal computers (Hoefer Scientific Instruments, San Francisco, CA). Photographs of agarose
gels were scanned by the densitometer, in reflectance mode, perpendicularly to the direction of DNA
migration, aligned with the unknotted DNA bands. To standardize the quantification of unknotted DNA,
known amounts of completely unknotted P4 DNA were electrophoresed, photographed, and
densitometrically scanned. The area under the curves corresponding to unknotted DNA bands were
calculated using the densitometry software and were plotted versus nanograms of unknotted DNA.
Amounts greater than 100 ng of unknotted DNA the unknotted DNA band intensity had plateaued and
there was no further increase in intensity with increasing amounts ofunknotted DNA.
Protein-Linked DNA Break
The production of protein-linked DNA breaks, by the agents, was evaluated by the method of Rowe et
a/.[9]. Approximately 107 L1210 or HeLa-S cells, growing in 50 ml RPMI-1640 with L-glutamine, 20%
fetal calf serum, penicillin (100,000 U/ml) and streptomycin (100,000 g/ml), were inoculated with 50 Ci
[6-3H]-thymidine (15.0 Ci/mmol) and allowed to incubate 20-24 hr. The cell suspension was then
centrifuged at 2,000 rpm for 10 min to pellet the cells. The supematant was removed by vacuum
aspiration and the cells were resuspended in fresh media, 37C. The resuspended cells were allowed to
incubate at 37C for 2-3 hr to wash out any unincorporated [methyl-3H]-thymidine. Then the cells were
equally divided among sample tubes, 0.125 ml/sample, four tubes per controls or sample compounds.
Controls include tubes, which contained no drugs, and tubes which contained VP-16 (final VP-16
concentration was 40 tM). Sample compounds (200 tM) in media, 0.125 ml, were added to 0.125 ml of
the cell suspension, so that the final concentration was 100 tM. All samples were allowed to incubate
hr, at 37C then 0.25 ml media containing drugs at 100M were added. Incubation continued for hr
additionally. Then 0.5 ml doubly concentrated lysis buffer [2.5% SDS, 10mM EDTA (pH 8), 0.8 mg/ml
calf thymus DNA] was added. Samples were warmed to 65C in a water bath and each was syringed
eight times, to sheer DNA fragments to uniform size, using a 3 ml syringe equipped with a 22 gauge
needle. Aliquots, 10 tl, were taken from each control tube containing no drugs, and were precipitated on
glass-fiber filters (GF/A) with ice cold 5% TCA, to determine the total number of dpm per sample. To
precipitate SDS, 0.25 ml 325 mM KC1 was added and mixed by inversion. The samples were placed on
ice for 10 min. Samples were centrifuged for min on a Fisher Scientific micro centrifuge (model 235C)
to pellet the precipitate. The supernatant was removed via vacuum aspiration followed by addition of a
wash buffer 10 mM Tris (pH 7.5), 2 mM EDTA (pH 8), 100 mM KC1, 0.1 mg/ml calf thymus DNA].
The precipitate was resuspended by vortexing and the samples were placed in a 65C water bath for 10
min. After the precipitate was completely dissolved, samples were placed on ice. After 5 min samples
were vortexed, and returned to ice for another 5 min. Microcentrifugation for another minute was
followed by removal of supernatant. The remaining pellets were then dissolved in distilled water at 65C
and transferred to scintillation vials. Scintiverse BD(R), 4 ml, was added to each scintillation vial and
samples were counted on a Packard Tricarb 4000 liquid scintillation spectrometer, and corrected for
quenching.
Interference Assay
The interference assay followed the procedures described for protein-linked DNA breaks, only differing
in that after the hr incubation with sample compound, an equal volume of VP-16 (80 tM) plus an
equimolar concentration of the appropriate sample compound was added to each sample [9]. The cells
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were allowed to incubate at 37C for an additional hr after the addition ofVP-16 solution. The cells were
then lysed and processed exactly as described above.
Cleavage-interference in vitro
The method used to assess interference with drug-induced topoisomerase II-mediated DNA cleavage in
vitro, was based on the procedure of Harker, et al.[ 10]. The Hind III-cut PBR322 DNA was end-labeled
with [_32p] dCTP (3000 Ci/mmol, ICN) using a commercial T4 polymerase labeling system. Cleavage
reactions of 50 ml contained 20 ng/ml labeled DNA, 30 mM Tris-HC1 [pH 7.6], 60 mM KC1, 8mM
MgC12, 3 mM ATP, 15 mM [-mercaptoethanol, and 30 mg/ml nuclease-free BSA. Topoisomerase II (4
U) was added to the enzyme control reaction and drug treatments, the latter being 40 mM VP-16 in the
absence or presence of amine borane derivatives. After a 30 min incubation at 37C, reactions were
divided equally and prepared for gel analysis with autoradiography and for quantifying protein-linked
DNA breaks using K+/SDS precipitation.
Dilute agar colony method
Following the modified method of Chu and Fischer 11 ], murine L1210 lymphoid leukemia cells were
grown suspended in agar as colonies. Cells (1 x 105), in RPMI-1640 with 10% fetal bovine serum, and
penicillin streptomycin amphotericin B (2 ml), were incubated for hr at 37C in the presence of
varying concentrations of experimental drugs, for drug treatments, or drug vehicle, DMSO, for controls.
Following incubation, cells were pelleted by centrifugation at 600 x g for 5 min. The media was
removed via aspiration, and the cell pellet was resuspended in fresh media of a volume equivalent to the
original (2 ml). The cells were diluted by serial dilution to a concentration of x 103 per milliliter. The
final dilution being made in sterile test tubes with a 0.13% agar solution of growth media, heated to 45C.
Agar dilutions were mixed by inversion and placed in test tube racks for incubation at 37C. Following 5
days of incubation, a solution of 0.01% neutral red (200tl) in growth media was gently layered on the
surface of each sample to diffuse into the colonies. On day 7, samples were decanted into 6-well plates
and colonies were counted using a colony counter over a 2 mm x 2mm grid. Results were expressed as
the percent of the number of colonies in untreated control.
Phosphorylation of Topoisomerase II
Phosphorylation of L1210 DNA or human topoisomerase II enzyme was measured by the method of
DeVore et al.[ 12]. Reactions containing reaction buffer (100tg/ml phosphatidyl serine, 50 mM Tris HC1
(pH 8.0), 25 mM NaC1, 7 mM MgC12, 100tM CaClz, and 30tM ATP, rat brain protein kinase C (4.55
U) (Sigma/Aldrich Chemical Co., St. Louis, MO), L1210 Topoisomerase II (4U/reaction), 10 tCi [y_32p]_
ATP (3000 Ci/mmol) (Dupont New England Nuclear, Reston, VA) and experimental drugs were
allowed to incubate for 30 min or 2 hr at 37C. Reactions were terminated by the addition of ml 10%
TCA. The acid insoluble precipitate was filtered onto GF/A glass fiber filter disks and counted for
radioactivity. Results were expressed as percent ofdpm of the untreated control. Standard protein kinase
inhibitors A3 and bisindolylmaleimide (Calbiochem-Novabiochem International, San Diego, CA) were
also assayed.
VP-16 Uptake and Efflux from L1210 Cells
[3H (G)]-VP-16 [lmCi] [etoposide, 300-900 mCi, Morevek Biochemicals] was incubated with 2.5 x 10
6
cells for 5 to 24 hr in RPMI-1640 + 15% FCS + P/S with compound 2 at 100 tM. Aliquots were removed
at time intervals from the reaction mixture, washed and counted according to the method of Feng et al.
[13]
Statistics
The mean and standard deviation are designated by "X + SD." The probable level of significance (p)
between test and control samples was determined by the Student’s "t" test with the raw data.
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Results
Piperidine carboxyborane 1, piperazine carboxyborane 2, morpholine carboxyborane 3, N-
methylmorpholine carboxyborane 4, 4-phenyl piperidine carboxyborane 5, 4-methyl piperidine
carboxyborane 6, and N-methyl imidazole carboxyborane 7 were effective cytotoxic agents in the L1210
and HeLa-S tumor screens. All of the EDs0 values were less than 4 pg/ml with the exception of
compound 3 in the L1210 screen [Table 2]. Generally the compounds were more effective in the HeLa-S
uterine carcinoma screen and were very comparable with standard antineoplastic agents used in these
screens.
Table 2
Compound
1
2
3
4
6
7
5FU
Ara-C
Cycloleucine
Hydroxyurea
Cytotoxic Evaluation of Heterocyclic Amine Carboxyboranes
N=4
L1210
1.74
3.34
4.44
2.68
3.56
2.85
2.46
1.41
2.76
2.67
2.67
EDs0 gg/ml
HeLa-S
1.92
1.60
2.14
2.48
1.23
1.71
1.97
2.47
2.13
1.98
1.96
Fig. 1
HeLa-S
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0
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4
The compounds were effective in reducing DNA synthesis greater than 50% in both the HeLa-S uterine
carcinoma and L1210 lymphoid leukemia cells over 60 min [Fig. and 2].
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Fig. 2
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Fig. 3
L1210 DNA Strand Scission for 24 hr
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DNA strand scission was evident in both cell lines after 24 hr. incubation at 100 tM with smaller
fragments appearing in the gradient ofboth L1210 and HeLa-S cells [Fig. 3 and 4].
Using the partially purified HeLa-S DNA topoisomerase II enzyme, subsequent studies demonstrated
that the compounds 1-7 were inhibitors at 200 tM. [Fig 5]. Using the L1210 partially purified DNA
topoisomerase enzyme was inhibited at _> 100 tM for the compounds. An in-depth study was performed
to determine if the compounds affected DNA topoisomerase II activity in a concentration range
consistent with the concentration needed for DNA synthesis inhibition. Compound 2 was selected for
this detailed study.
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Fig. 4
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Fig. 7
L1210 VP16 Induced DNA Protein Linked Breaks at I Hr
Percent of vP-
16 Control
100
60
40
20
Control VP-16 Cpd # Cpd #
at 40 2+VP- 3+VP-
uM 16 16
Drugs 100 uM
L1210 cell DNA protein linked breaks were not evident after hr incubation with compounds 2 or 3 at
100 tM, alone [Fig 6], but the standard VP-16 at 40 tM did afford breaks at hr. Combinations of VP-
16 (40 tM) with compounds 2 or 3 (100 tM) did not demonstrate an increasing number ofDNA linked
breaks through 3 hr [Fig 7]. On the other hand, compounds 2 and 3 appeared synergistic with VP-16
affording additional breaks at 15 and 24 hr which were significantly greater in magnitude than with VP-
16 alone [Fig. 8 and 9]. These studies suggested that the heterocyclic amine carboxyboranes functioned
Fig. 8
L1210 VP-16 Induced DNA Protein Linked Breaks Over 15 Hrs
Percent VP-16Control
2(
1
1
= Control
mVP-16
Cpd 3 mCpd 3 + VP-16
0 1 3 6 15
Time Hours
in a manner different than VP-16 in affording DNA protein linked breaks and this effect was delayed
after the observedDNA synthesis inhibition at hr of-- 50%.
The Hind III-cut PBR322 DNA end-labeled with [ct-aZP] dCTP study also confLrmed that compound 2
was not a direct inhibitor of DNA topoisomerase II activity from 1 to 100 lxM, but it does appear to be
enhancing the action of VP-16 causing DNA breaks at 10 and 100 tM suggesting that the heterocyclic
amines function by some other mechanism than binding to the same site on the enzyme as VP-16 [Fig
10].
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Fig. 9
L1210 VP-16 DNA Protein Linked Breaks Over 24 Hr
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On the other hand, combinations ofVP-16 at 40 tM and compound 2 at 100 tM were shown to enhance
L1210 cell death [Fig 11], inhibit L1210 DNA synthesis [Fig 12] and reduce dilute agar colony growth of
surviving cells [Fig 13]. This enhancement of the reduction of these cellular
Fig. 10
Hind III End-Label PBR32
CPM
DNA Topo
VP-16
2at 100uM
2at 10uM
2at luM
VP-1640 uM
noVP-16
parameters was not equal to a simple addition of the effects of VP-16 + the agent. By using 3H VP-16,
the uptake and effiux of VP-16 in L1210 cells was shown not to be enhanced by the presence of
compound 2 at 100 tM [Fig 14 ]. In fact, compound 2 reduced the concentration of labeled VP-16
uptake into the L1210 cells after 6 min. Thus, the compound did not cause the accumulation ofVP-16 in
the cancer cell thus causing more cytotoxic effects by this mechanism.
Combination studies of VP-16 with compound 2 demonstrate that use of both agents together produce a
significant increases in small fragments of DNA in the gradient [Fig 15]. VP-16 alone caused DNA
fragmentation with medium size DNA fragments, whereas when the drug was added in combination this
resulted in smaller DNA fragments. Nevertheless, the drug alone was capable of producing small
fragments ofDNA. The phosphorylation by protein kinase C ofL1210 DNA topoisomerase II as well as
human DNA topoisomerase II was found to be reduced by compound 2 whereas VP-16 caused an
elevation of the phosphorylation by PKC. The magnitude of reduction afforded by compound 2 was
similar to known inhibitors of protein kinase C activity [Table 3] and was delayed in time with the
highest inhibition ofphosphorylation by PKC at 2 hr.
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Fig. 11 L1210 Cell Growth
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Fig. 14
DPM
VP-16 Uptake into L1210
40000
35000
30000
25000
20000
15000
10000
5000
0
0 6 15 25
Time min.
VP-16at40 uM
+ Cpd 2 100 uM
Fig. 15
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Table 3: Inhibition of Protein Kinase C-Dependent Phosphorylation of Llzl0 and Human DNA
Topoisomerase II by Amine Carboxyborane Derivatives After a 0.5 or 2 Hr Exposure.
L121o Topoisomerase II Human Topois0merase II
30 min 2 hr 30 min 2 hr
mean + s.d. mean + s.d. mean + s.d. mean + s.d.
’Cool 100+16 100+8 100+23 100+17
2’ (100 ktM’) 141 + 2’1 78 + 9 * 79 + 13 70 + 16
VP16"(i’oo tM) 1’5’7 + 40* 160’+70" -
Bisiidolylmaleimide I (20 27-3" "18 +3 *** 12 + ** "4 +_ ***
nM)
"A3 (100 tM) 77+ 3*’ 66 + 14 * 36 + 4 ** ["68 +_ 14"
(N 3); * p < 0.05; ** p < 0.02; *** p < 0.001; 1590 cpm; 418 cpm; 1847 cpm;
d 14050 cpm
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Discussion
The heterocyclic amine carboxyborane adducts have more than one mode of action in affording tumor
cell death. Obviously the reported inhibition of enzyme activities involved in the regulation of the purine
pathway by the compounds from 25 to 100 tM in L1210 cells will result in cell death by reducing
deoxyribonucleotide pools ]. DNA strand scission has also been linked to tumor cell death or apoptosis.
Since the L1210 growth study demonstrated that longer than 24 hr was required to observe significant
changes in cell number in the presence of these compounds, this suggests that the heterocyclic amine
carboxyboranes are altering cellular biochemical events later than 60 min. Thus, there are secondary
events afforded by the drugs which are also important in causing cancer cell death. These agents do not
appear to be L1210 DNA topoisomerase II inhibitors at 100 tM concentrations consistent with the
concentration of drug for the observed inhibition ofDNA synthesis and DNA fragmentation. The agents
were additive with the effects ofVP-16 in inducing DNA protein linked breaks after 6 hr incubation in a
concentration dependent manner. The study would suggest that the heterocyclic amine carboxyboranes
did not bind to the same site on DNA topoisomerase II enzyme as VP-16 since they produced no
cleavage product when used alone from to 24 hr. The agents appeared to be acting in a manner other
than VP-16 on the DNA topoisomerase II enzyme to enhance the ability of VP-16 to afford cleavable
product, i.e. DNA protein linked breaks. VP-16 is passively taken up by cancer cells but its efflux is by
the p-glycoprotein transporter. This transporter can be blocked by a variety of agents, i.e. verapamil, to
block the efflux ofVP-16 and increase cell death. However, the heterocyclic amine carboxyboranes did
not cause increased accumulation ofVP-16 in L1210 cells. Agents which block phosphorylation by PKC
ofDNA topoisomerase II reduce its catalytic action and cause more DNA protein linked breaks followed
by apoptosis [12, 14-15]. These studies have demonstrated that P-16 actually stimulates
phosphorylation of L1210 and human DNA topoisomerase II whereas the heterocyclic amine
carboxyboranes cause a reduction in phosphorylation of the enzyme which is related to increase in
cleavable products and cell death.
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